IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Natus Medical Incorporated (“Natus or the “Company”) (Nasdaq: BABY). Investors who purchased or otherwise acquired shares between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”) are encouraged to contact the Firm in advance of the March 31, 2017 lead plaintiff motion deadline.
If you purchased shares of Natus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Natus made materially false and/or misleading statements, and/or failed to disclose that: the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; that Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; that the Company’s receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and that as a result of the above, Natus was not going to achieve the increased guidance provided by the Company which lacked a reasonable basis. When this information reached the public, shares of Natus fell in value.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.